BioMedNewsBreaks

TuesdaySep 15, 2026 12:29 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit 

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.  Quantum BioPharma (NASDAQ: QNTM) a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, announced its participation in the 3rd Annual ArcStone-Kingswood Growth Summit on Sept. 16, 2026, in Toronto, where Co-founder and Executive Co-chairman Anthony Durkacz will present the company’s recent milestones and future growth strategy. Quantum BioPharma recently announced that the U.S. Food and Drug Administration approved its Investigational New Drug application for Lucid-MS, allowing the company to begin Phase 2 trials of its patented, first-in-class multiple sclerosis program in patients with progressive MS. To…

Continue Reading

MondaySep 14, 2026 1:20 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in NetworkNewsAudio APR Highlighting FDA Clearance of Lucid-MS IND

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.  Quantum BioPharma (NASDAQ: QNTM) was featured in a NetworkNewsAudio Audio Press Release titled “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach,” highlighting FDA clearance of the company’s Investigational New Drug (“IND”) application for Lucid-MS. According to the company, the approximately 15,000-page IND submission included a comprehensive package of pharmacology, toxicology and manufacturing data, with the clearance allowing Quantum BioPharma to move directly into a randomized, double-blind, placebo-controlled Phase 2 trial evaluating Lucid-MS in people with multiple sclerosis. Lucid-MS is the company’s patented…

Continue Reading

FridaySep 11, 2026 11:31 am

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports First Half 2026 Results, Advances GelrinC(R) Pivotal Trial 

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, reported financial results for the six months ended June 30, 2026 and provided a corporate and clinical update. The company has recruited and treated 43 of 80 patients in its pivotal Phase III GelrinC(R) U.S. trial and now expects to complete enrollment around year-end. Regentis also expanded its U.S. and European clinical networks, advanced preparations for European commercialization and received regulatory approval in Europe for a new solvent-free manufacturing process that increases GelrinC(R) production yield by 400%. For the first half, Regentis reported a net loss of approximately $2.6 million, or $0.44 per share, compared…

Continue Reading

FridaySep 11, 2026 10:21 am

BioMedNewsBreaks – Nanox Imaging Ltd. (NASDAQ: NNOX) Signs Nanox.ARC Distribution Agreement for Costa Rica

Nanox (NASDAQ: NNOX) announced a distribution agreement with Costa Rica-based medical equipment distributor SOLME RC, S.A. to market and support the Nanox.ARC, a multi-source digital tomosynthesis system designed to expand access to 3D medical imaging. SOLME will oversee marketing, distribution, installation, training and ongoing technical support in Costa Rica, where it is a registered supplier to the Caja Costarricense de Seguro Social (“CCSS”), the country principal purchaser and provider of hospital services. Commercialization will follow applicable regulatory registration, including an initial six-month proof-of-concept device registration period before full registration, and Costa Rica represents Nanox third Latin American market this year following…

Continue Reading

FridaySep 11, 2026 9:20 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in BioMedWire Editorial on Lucid-MS Phase 2 Trial

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) announced its placement in a BioMedWire editorial examining the potential of Lucid-MS to address limitations of existing multiple sclerosis (“MS”) treatments. The editorial highlights Quantum BioPharma’s U.S. Food and Drug Administration (“FDA”) clearance to launch a phase 2 trial of Lucid-MS, a patented, first-in-class candidate designed to protect and potentially rebuild the myelin sheath rather than suppress the immune system. According to the publication, the trial would mark the first time a drug based on this mechanism is tested in people…

Continue Reading

ThursdaySep 10, 2026 1:10 pm

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Bolsters Scientific Leadership Ahead of BiTAC(R) Clinical Development

VERAXA Biotech (NASDAQ: VRXA) recently appointed antibody therapeutics specialist Dr. Christoph Erkel as its chief scientific officer, taking responsibility for advancing the company’s proprietary BiTAC(R) technology and broader oncology pipeline toward clinical development. The company’s lead BiTAC-TCE program uses a conditionally active, dual-targeting approach designed to selectively activate T cells against cancer cells while potentially limiting effects on healthy tissue. Recent scientific advice from Germany’s Paul-Ehrlich-Institute provided additional clarity around the program’s proposed non-clinical development strategy, while preclinical data presented at the AACR Annual Meeting showed selective activity against cells expressing both target molecules. Beyond BiTAC, VERAXA is developing bispecific antibody-drug…

Continue Reading

ThursdaySep 10, 2026 12:22 pm

BioMedNewsBreaks — Earth Science Tech Inc.’s (ETST) B2B-B2C Healthcare Platform Powers Continued Revenue Growth

Earth Science Tech (OTC: ETST) is positioning itself as a vertically integrated healthcare company through its subsidiaries RxCompoundStore, Mister Meds, and Peaks Curative, combining compounding pharmacy, telemedicine, clinical support, and fulfillment capabilities. Its B2B and B2C business model allows the company to serve independent clinics while also selling customized medications directly to consumers, creating diversified revenue streams across physical and digital healthcare operations. In FY2026, ETST reported revenue of $35.7 million, up from $33.1 million in FY2025 and $11.95 million in FY2024, while also reporting positive operating cash flow and a stronger balance sheet. The company reduced total liabilities from $3.146…

Continue Reading

ThursdaySep 10, 2026 10:00 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) is advancing Lucid-MS toward a randomized, double-blind, placebo-controlled phase 2 trial in multiple sclerosis (“MS”) following U.S. Food and Drug Administration (“FDA”) clearance of its Investigational New Drug (“IND”) application. Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (“PAD2”) designed to target demyelination directly rather than suppress the immune system. The editorial also highlights Quantum BioPharma research collaboration with Massachusetts General Hospital and Harvard Medical School involving the [¹⁸F]3F4AP PET imaging tracer, which is being evaluated as…

Continue Reading

ThursdaySep 10, 2026 9:30 am

BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in Morgan Stanley Global Healthcare Conference

This article has been disseminated on behalf of Helus Pharma and may include paid advertising. Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced that CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The fireside chat will be webcast live Sept. 16 at 8:30 a.m. EDT, with a replay available on the Events & Presentations page of Helus Pharma investor relations website. To view the full press release, visit https://ibn.fm/r0jfC About Helus Pharma Helus Pharma(TM), the commercial operating name of Cybin Inc., founded in 2019 (the “Company”),…

Continue Reading

ThursdaySep 10, 2026 9:10 am

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) CMO Discusses ONC010, Novel PNKP Target in BioMedWire Podcast

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) Chief Medical Officer Dr. Islam Mohamed joined IBN BioMedWire Podcast to discuss lead drug candidate ONC010, the company novel approach to targeting the DNA repair enzyme polynucleotide kinase phosphatase (“PNKP”) and its planned first-in-human clinical program. Mohamed highlighted ONC010 two selectivity mechanisms — synthetic lethality designed to limit drug lethality to cancer cells that have lost PTEN or SHP-1 and nanoparticle delivery intended to concentrate the drug within tumor tissue — as well as preclinical…

Continue Reading